SEC Form 4 · accession 0001178913-18-000259
Foamix Pharmaceuticals Ltd. · FOMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Yohan Hazot
Officer — VP Pharmaceutical Development
Period of report
Jan 1, 2018
Accepted (ET)
Jan 24, 2018 · 8:21 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001606645
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2 | Jan 1, 2018 | M | 4,575 | $0.00 | A | 27,300 | D | |
| Ordinary SharesF1,F2 | Jan 15, 2018 | M | 562 | $0.00 | A | 27,300 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Share UnitsF1,F5,F3 | $0.00 | Jan 1, 2018 | M | 4,575 | D | — | — | Ordinary Shares | 4,575 | 0 | D |
| Restricted Share UnitsF1,F5,F4 | $0.00 | Jan 15, 2018 | M | 562 | D | — | — | Ordinary Shares | 562 | 0 | D |
Explanation of responses
- F1This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer.
- F2The issuer's method of reporting restricted share units has been revised to report such grants in Table I rather than as previously reported in Table II. Accordingly, this amount includes (i) 6,184 ordinary shares previously reported in Table I of the reporting person's Form 3, (ii) 4,575 ordinary shares underlying restricted share units that vested on January 1, 2018, (iii) 562 ordinary shares underlying restricted share units that vested on January 15, 2018 and (iv) 15,979 ordinary shares subject to unvested restricted share units that were previously reported in Table II of the reporting person's Form 3 as a derivative security.
- F3The ordinary shares underlying this restricted share unit award vest over a period of four years (25% on January 1, 2018 and 6.25% every three months thereafter) ending January 1, 2021.
- F4The ordinary shares underlying this restricted share unit award vest in equal installments every three months over the vesting period beginning January 15, 2018 and ending January 15, 2019.
- F5This class of restricted share units is included in Column 5 of Table I above.